[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Bruna J, Velasco R: [Gliomatosis cerebri]. Neurologia; 2010 Apr;25(3):143-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gliomatosis cerebri].
  • [Transliterated title] Gliomatosis cerebri.
  • INTRODUCTION: gliomatosis cerebri (GC) is a rare, diffusely growing glial tumour characterized by extensive brain infiltration.
  • The diversity of histological subtype and grade on presentation among different subjects, in addition to the usually poor response to treatment make GC an uncertain entity where many questions still remain unanswered.
  • One article in this issue of NEUROLOGIA describes a series of 22 patients with GC, where clinical, therapeutic and outcome results are detailed.
  • DEVELOPMENT: clinical presentation of GC is non-specific and, although the neuroimage is characteristic, the spectrum of differential diagnosis is wide.
  • Therefore, variability of outcome and response to therapy is the rule.
  • Evidence on therapeutic strategies is based on case-series.
  • According to this, the optimal treatment is not well established.
  • Part of current research is focused on identifying molecular predictor factors of response to chemotherapy.
  • CONCLUSIONS: the addition of chemotherapy in the classic treatment schedule based on radiotherapy seems to produce better responses in GC patients.
  • Phase III multi-centre trials to evaluate different therapeutic strategies in GC are essential.
  • [MeSH-major] Brain Neoplasms. Neoplasms, Neuroepithelial
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Humans. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elservier España, S.L. All rights reserved.
  • (PMID = 20492859.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Novillo López ME, Gómez-Ibáñez A, Rosenfeld M, Dalmau J: [Gliomatosis cerebri: review of 22 patients]. Neurologia; 2010 Apr;25(3):168-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gliomatosis cerebri: review of 22 patients].
  • [Transliterated title] Gliomatosis cerebral: estudio de 22 pacientes.
  • INTRODUCTION: gliomatosis cerebri is a diffuse astrocytic neoplasm that involves more than two lobes of the brain.
  • Treatment is not well defined and the prognosis is considered poor.
  • METHODS: retrospective analysis of 22 patients with gliomatosis cerebri.
  • Seventeen patients received treatment with chemotherapy, radiotherapy or both, and 12 patients (70.6%) had a clinical or radiological response.
  • The median follow-up was 13 months, median progression free survival 6 months, and median survival 9,5 months (15 months if the patients received treatment).
  • CONCLUSIONS: gliomatosis cerebri has a variable clinical course.
  • Treatment often results in clinical responses.
  • In this study de median survival of patients who received treatment was similar to that reported in series of glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms. Neoplasms, Neuroepithelial

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elservier España, S.L. All rights reserved.
  • (PMID = 20492863.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Kong DS, Kim ST, Lee JI, Suh YL, Lim DH, Kim WS, Kwon KH, Park K, Kim JH, Nam DH: Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC Cancer; 2010;10:424
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of adjuvant chemotherapy for gliomatosis cerebri.
  • BACKGROUND: Gliomatosis cerebri (GC) is characterized by a diffuse infiltration of tumor cells throughout CNS, however, few details are available about the chemotherapeutic effect on GC.
  • The aim of this study was to investigate its clinical course and to determine the efficacy of chemotherapy for GC.
  • To determine the efficacy of chemotherapy for GC, we retrospectively reviewed their clinical courses.
  • The study cohort was divided into 2 groups, those with and without receiving post-radiotherapy adjuvant chemotherapy such as temozolomide or nitrosourea-based chemotherapy.
  • RESULTS: Nineteen patients with adjuvant chemotherapy were assigned to the chemotreatment group and 18 with radiotherapy alone were assigned to the control group.
  • Time to progression for these groups were 16.0 and 6.0 months, respectively (p = 0.007).
  • Overall review of the clinical course of patients with GC provided that early appearance of new contrast-enhancing lesions within 6 months from the initial diagnosis and higher histological grade were closely associated with poor survival (p < 0.001 and p = 0.008).
  • CONCLUSION: Adjuvant chemotherapy following radiotherapy could prolong the survival in patients with GC.
  • In addition, newly developed contrast-enhanced lesions on the follow-up MR images indicate the progression of GC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / complications. Brain Neoplasms / radiotherapy. Neoplasms, Neuroepithelial / drug therapy. Neoplasms, Neuroepithelial / etiology. Neoplasms, Radiation-Induced / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carmustine / administration & dosage. Chemotherapy, Adjuvant. Child. Cohort Studies. Combined Modality Therapy. Cranial Irradiation. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Neoplasm Staging. Procarbazine / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1137-46 [12829152.001]
  • [Cites] Neurology. 2008 Feb 19;70(8):590-5 [18285534.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Sep;24(8):1554-9 [13679270.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):270-5 [15277619.001]
  • [Cites] Neurology. 1974 Jun;24(6):504-11 [4499966.001]
  • [Cites] Clin Neuropathol. 1985 Jul-Aug;4(4):135-48 [4053456.001]
  • [Cites] Neuroradiology. 1987;29(1):15-8 [3822096.001]
  • [Cites] AJR Am J Roentgenol. 1993 Oct;161(4):859-62 [8372774.001]
  • [Cites] J Child Neurol. 1995 Jan;10(1):37-45 [7539465.001]
  • [Cites] Radiology. 1996 Mar;198(3):831-5 [8628879.001]
  • [Cites] Neuroradiology. 1996 Jul;38(5):444-8 [8837088.001]
  • [Cites] Scott Med J. 1998 Jun;43(3):84-6 [9682295.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):755-62 [9810441.001]
  • [Cites] Pediatr Neurol. 1999 Feb;20(2):148-51 [10082346.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):557-65 [15560713.001]
  • [Cites] Rev Neurol (Paris). 2005 Feb;161(2):173-81 [15798516.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16466-71 [17056721.001]
  • [Cites] Magn Reson Imaging. 2007 Feb;25(2):238-43 [17275620.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Oncol Rep. 2008 Mar;19(3):639-43 [18288395.001]
  • [Cites] Neurol Res. 2009 Nov;31(9):931-9 [19215664.001]
  • [Cites] Eur Radiol. 2001;11(2):303-8 [11218032.001]
  • [Cites] Neuroradiology. 2000 Aug;42(8):612-5 [10997568.001]
  • [Cites] J Neurosurg. 2010 Jan;112(1):10-7 [19361270.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):249-59 [12241123.001]
  • [Cites] Magn Reson Med. 2003 May;49(5):848-55 [12704767.001]
  • [Cites] Acta Neuropathol. 2003 Jun;105(6):529-36 [12734658.001]
  • [Cites] NMR Biomed. 2007 Oct;20(6):566-77 [17221937.001]
  • [Cites] Neurosurgery. 2003 Aug;53(2):261-71; discussion 271 [12925240.001]
  • (PMID = 20704759.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ PMC2933624
  •  go-up   go-down


Advertisement
4. Inamasu J, Nakatsukasa M, Kuramae T, Masuda Y, Tomiyasu K, Yamada T: Gliomatosis cerebri mimicking chemotherapy-induced leukoencephalopathy in a patient with non-Hodgkin's lymphoma. Intern Med; 2010;49(7):701-5
Genetic Alliance. consumer health - Gliomatosis Cerebri.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomatosis cerebri mimicking chemotherapy-induced leukoencephalopathy in a patient with non-Hodgkin's lymphoma.
  • Patients with hematological malignancies may develop white matter lesions, which are usually associated with chemotherapy.
  • Magnetic resonance imaging (MRI) is the imaging modality of choice for identifying chemotherapy-induced, or "toxic", leukoencephalopathy.
  • Brain biopsy in patients with hematological malignancies suspected of sustaining toxic leukoencephalopathy has rarely been performed, because its characteristic MRI findings are considered pathognomotic.
  • We describe a case with white matter lesions that developed in an elderly man treated for non-Hodgkin's lymphoma.
  • The lesions, initially diagnosed with toxic leukoencephalopathy based on MRI findings, turned out to be gliomatosis cerebri.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukoencephalopathies / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Neoplasms, Neuroepithelial / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371962.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Sanson M, Napolitano M, Cartalat-Carel S, Taillibert S: [Gliomatosis cerebri]. Rev Neurol (Paris); 2005 Feb;161(2):173-81
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gliomatosis cerebri].
  • INTRODUCTION: Gliomatosis cerebri (GC) is defined as a diffuse neoplastic glial cell infiltration of the brain involving more than two cerebral lobes and, occasionally, the infratentorial structures or the spinal cord.
  • Diagnosis and management of GC are difficult.
  • Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable and large field radiotherapy carries the risk of severe toxicity.
  • Survival (median=14.5 months) is also better for young patients, with high performance status, low-grade gliomatosis, and oligodendroglial subtype.
  • Initial chemotherapy results in nearly 30 percent clinical or radiological improvement.
  • PERSPECTIVE: Genotyping could be helpful to predict the response to chemotherapy in GC patients.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Humans. Male. Prognosis. Terminology as Topic

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798516.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


6. Maton B, Resnick T, Jayakar P, Morrison G, Duchowny M: Epilepsy surgery in children with gliomatosis cerebri. Epilepsia; 2007 Aug;48(8):1485-90
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epilepsy surgery in children with gliomatosis cerebri.
  • PURPOSE: Gliomatosis cerebri (GC) is a rare neoplastic disorder that may present as intractable epilepsy during early life.
  • We report our experience regarding the evaluation and the surgical treatment of epilepsy in this population.
  • Procedure was individually tailored based on the presurgical evaluation.
  • Brain MRI revealed widespread hemispheric involvement (n = 3) or infiltration of the temporal lobe and basal ganglia (n = 1).
  • Chemotherapy was associated in three cases.
  • Epilepsy surgery is an effective therapy that can improve quality of life.
  • [MeSH-minor] Age Factors. Brain / pathology. Brain Mapping. Child. Child, Preschool. Electroencephalography / statistics & numerical data. Functional Laterality / physiology. Hemispherectomy. Humans. Infant. Magnetic Resonance Imaging. Male. Quality of Life. Temporal Lobe / pathology. Temporal Lobe / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565595.001).
  • [ISSN] 0013-9580
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Armstrong GT, Phillips PC, Rorke-Adams LB, Judkins AR, Localio AR, Fisher MJ: Gliomatosis cerebri: 20 years of experience at the Children's Hospital of Philadelphia. Cancer; 2006 Oct 1;107(7):1597-606
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomatosis cerebri: 20 years of experience at the Children's Hospital of Philadelphia.
  • BACKGROUND: Gliomatosis cerebri (GC) is a rare and typically fatal glial neoplasm of the central nervous system.
  • In this report, the authors describe the largest cohort of children to date with GC and explore relations between potential prognostic factors, treatment, and survival.
  • Twelve patients received cranial irradiation, and 8 of those patients received adjuvant chemotherapy.
  • A single patient age 1 year received chemotherapy alone.
  • The time to progression was prolonged significantly for patients who had no evidence of tumor enhancement on imaging studies (P = .03).
  • When survival data from patients reported in the literature were combined with the CHOP cohort, treatment prolonged OS significantly (P = .003).
  • CONCLUSIONS: The outcome of pediatric patients with GC was extremely poor; however, the current results indicated that treatment may prolong OS.
  • Age < 10 years and contrast enhancement on magnetic resonance imaging studies at diagnosis may be risk factors for shorter survival in pediatric patients with GC.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / therapy. Glioma / mortality. Glioma / therapy. Neoplasms, Neuroepithelial / mortality. Neoplasms, Neuroepithelial / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Female. Hospitals, Pediatric. Humans. Magnetic Resonance Imaging. Male. Philadelphia. Treatment Outcome

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955507.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Elshaikh MA, Stevens GH, Peereboom DM, Cohen BH, Prayson RA, Lee SY, Barnett GH, Suh JH: Gliomatosis cerebri: treatment results with radiotherapy alone. Cancer; 2002 Nov 1;95(9):2027-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomatosis cerebri: treatment results with radiotherapy alone.
  • BACKGROUND: Gliomatosis cerebri (GC) is a rare primary brain tumor characterized by proliferation of neoplastic glial cells that typically involve multiple brain areas, with preservation of brain structures and sparing of neurons.
  • The optimal therapeutic strategy is not well established.
  • METHODS: Between 1980 and 2001, 12 patients with GC were identified, representing less than 1% of all patients with primary brain neoplasms treated at the Cleveland Clinic.
  • RESULTS: All 12 patients had brain biopsies between March 1986 and July 2001 (seven males, five females, with a median age of 53 years [range, 13-85 years]).
  • Median Karnofsky performance status at the time of presentation was 70 (range, 40-90).
  • Eight patients received radiation treatment to the brain as the only treatment, and four received neither radiation nor chemotherapy.
  • The median dose of megavoltage radiation was 55.4 Gy (range, 45-61.2 Gy).
  • Of the eight patients who received brain radiotherapy, the clinical and radiologic follow-up findings improved in three patients, stabilized in three patients, and worsened in two patients.
  • The median survival for the eight patients who received brain radiotherapy was 11.4 months.
  • Two of the eight patients who received radiotherapy were alive at the time of writing.
  • The four patients who did not receive radiotherapy died of the disease at 0.6, 1.0, 1.9, and 2.4 months after diagnosis.
  • CONCLUSIONS: Gliomatosis cerebri is associated with poor survival.
  • Although brain radiotherapy controlled or stabilized disease progression in most patients, the overall survival after brain radiotherapy alone was not satisfactory.
  • More aggressive therapy may be needed.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Neoplasms, Neuroepithelial / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / mortality. Astrocytoma / radiotherapy. Female. Glioma / diagnosis. Glioma / mortality. Glioma / radiotherapy. Humans. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12404298.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


9. Lodi R, Setola E, Tonon C, Ambrosetto P, Franceschi E, Crinò L, Barbiroli B, Cortelli P: Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration. Magn Reson Imaging; 2003 Nov;21(9):1003-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration.
  • Gliomatosis cerebri is a rare form of diffusely infiltrating glioma that is typically resistant to conventional chemotherapy and radiation therapy and carries a poor prognosis.
  • Temozolomide has shown antineoplastic activity against malignant gliomas and more recently was beneficial in one patient with gliomatosis cerebri.
  • To make an objective assessment of the effect of long-term temozolomide administration in a patient with gliomatosis cerebri we used brain proton magnetic resonance spectroscopy and structural MRI.
  • A 46-year-old man with gliomatosis cerebri was treated with temozolomide (200 mg/m(2) per day for 5 days every 28 days).
  • Twenty cycles of temozolomide resulted in a marked reduction in choline and scyllo-inositol content, as detected using brain proton MR spectroscopy, indicating reduced tumor cellularity and/or growth rate.
  • A left pyramidal syndrome, present at the start of the treatment, disappeared.
  • Our observation lends support to larger clinical trials evaluating the use of temozolomide to treat this brain tumor.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Neoplasms, Neuroepithelial / drug therapy
  • [MeSH-minor] Brain / drug effects. Brain / metabolism. Brain / pathology. Humans. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14684203.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


10. Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY, ANOCEF group: Initial chemotherapy in gliomatosis cerebri. Neurology; 2004 Jul 27;63(2):270-5
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial chemotherapy in gliomatosis cerebri.
  • BACKGROUND: Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity.
  • In this setting, initial chemotherapy warrants further investigation.
  • METHODS: The authors treated 63 consecutive patients with GC with initial chemotherapy consisting of either PCV (procarbazine, 60 mg/m2 on days 8 to 21; CCNU, 110 mg/m2 on day 1; and vincristine, 1.4 mg/m2 on days 8 and 29) or temozolomide (TMZ; 150 to 200 mg/m2 for 5 days every 4 weeks).
  • GC was initially present at diagnosis in 49 patients (primary GC), whereas 14 patients with a circumscribed glioma at onset developed secondary GC after a median follow-up period of 5.11 years.
  • CONCLUSION: Initial chemotherapy is useful for some patients with gliomatosis cerebri.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Neoplasms, Neuroepithelial / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Female. Hematologic Diseases / chemically induced. Humans. Karnofsky Performance Status. Lomustine / administration & dosage. Lomustine / adverse effects. Magnetic Resonance Imaging. Male. Middle Aged. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy. Procarbazine / administration & dosage. Procarbazine / adverse effects. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2004 Jul 27;63(2):204-5 [15277608.001]
  • (PMID = 15277619.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; PCV protocol
  •  go-up   go-down


11. Shahar E, Kramer U, Nass D, Savitzki D: Epilepsia partialis continua associated with widespread gliomatosis cerebri. Pediatr Neurol; 2002 Nov;27(5):392-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epilepsia partialis continua associated with widespread gliomatosis cerebri.
  • We report an uncommon association of intractable epilepsia partialis continua that was the main presentation of widespread gliomatosis cerebri in two females.
  • Evaluation for Rasmussen's encephalitis, focal cortical dysplasia, or a gliomatous process was conducted; the patients underwent a stereotactic brain biopsy in which the histologic findings were compatible with gliomatosis cerebri with diffuse widespread infiltration of glioma cells with no constitution of a circumscribed tumor mass.
  • The first patient was treated with cranial radiation, chemotherapy, steroids, and combined antiepileptic therapy.
  • The focal seizures gradually but markedly decreased in frequency, and sensory impairment abated within 18 months after establishment of the diagnosis and ensuing therapy.
  • The second female died 2 years after presentation despite massive chemotherapy and antiepileptic medications.
  • Although rare, gliomatosis cerebri should be taken into account in the differential diagnosis of epilepsia partialis continua in children to facilitate a rapid diagnosis and initiation of prompt treatment of this rare disorder that may respond to a concurrent effective combination of cranial radiation, chemotherapy, and antiepileptic medications.
  • [MeSH-major] Epilepsia Partialis Continua / diagnosis. Neoplasms, Neuroepithelial / diagnosis
  • [MeSH-minor] Brain / pathology. Child. Child, Preschool. Combined Modality Therapy. Diagnosis, Differential. Electroencephalography. Encephalitis / diagnosis. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Myoclonus / etiology

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12504209.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Levin N, Gomori JM, Siegal T: Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. Neurology; 2004 Jul 27;63(2):354-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
  • The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known.
  • Eleven radiotherapy-naive patients received a median number of 10 treatment cycles of temozolomide.
  • An objective response was documented in 45%, and the median time to tumor progression was 13 months with a progression-free survival of 55% at 12 months.
  • These results indicate that radiotherapy to extensive brain regions can be deferred until progressive disease is observed.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Neoplasms, Neuroepithelial / drug therapy
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Female. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Life Tables. Male. Middle Aged. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2004 Jul 27;63(2):204-5 [15277608.001]
  • (PMID = 15277636.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


13. Knox MK, Ménard C, Mason WP: Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebri. J Neurooncol; 2010 Oct;100(1):145-9
Genetic Alliance. consumer health - Gliomatosis Cerebri.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebri.
  • Leptomeningeal gliomatosis is a known, yet uncommon, complication of malignant gliomas.
  • Gliomatosis cerebri is also a rare disease, characterized by extensive diffuse infiltration of neoplastic glial cells.
  • For both entities, limited data exist to guide treatment and prognosis is poor.
  • We describe the case of a patient who presented with symptoms of increased intracranial pressure and diffuse leptomeningeal enhancement in the brain and spinal cord on MRI.
  • After a period of surveillance, intraparenchymal lesions developed in association with widespread diffuse infiltration.
  • The diagnosis of gliomatosis cerebri with diffuse leptomeningeal gliomatosis was established in hindsight.
  • Initial treatment consisted of six cycles of temozolomide chemotherapy.
  • [MeSH-minor] Adult. Brain / pathology. Female. Humans. Magnetic Resonance Imaging / methods. Spinal Cord / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1998 Oct;50(4):356-62; discussion 362 [9817460.001]
  • [Cites] J Neurooncol. 1999 Sep;44(2):163-8 [10619500.001]
  • [Cites] Neurosurgery. 1989 Oct;25(4):533-40 [2797391.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):201-5 [16200347.001]
  • [Cites] Neurology. 1992 Jan;42(1):252-4 [1310353.001]
  • [Cites] J Child Neurol. 1995 Jan;10(1):37-45 [7539465.001]
  • [Cites] Neurosurgery. 2003 Feb;52(2):324-29; discussion 330 [12535360.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):247-53 [12533659.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):270-5 [15277619.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):209-16 [17031563.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):161-7 [9524095.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):354-6 [15277636.001]
  • [Cites] Clin Neurol Neurosurg. 2000 Dec;102(4):223-226 [11154809.001]
  • [Cites] J Neurooncol. 1993 Mar;15(3):275-83 [8360714.001]
  • [Cites] Clin Neuropathol. 2009 Mar-Apr;28(2):73-82 [19353837.001]
  • [Cites] Acta Neurol Scand. 1989 Feb;79(2):133-9 [2711819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1137-46 [12829152.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):45-9 [8455062.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] J Clin Neurosci. 2006 Feb;13(2):298-301 [16431108.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • (PMID = 20146082.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kuroki K, Sugiyama K, Taguchi H, Yukawa O, Kurokawa M, Kajiwara Y, Usui S, Kurisu K: [Gliomatosis cerebri. Report of two cases]. No Shinkei Geka; 2006 May;34(5):513-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gliomatosis cerebri. Report of two cases].
  • Gliomatosis cerebri is a rare tumor of the central nervous system, and here we report two cases of this tumor.
  • The patient was diagnosed with gliomatosis cerebri, and surgery and whole brain radiation at 44Gy were performed.
  • A specimen obtained by open biopsy revealed anaplastic oligodendroglioma, which was diagnosed as gliomatosis cerebri.
  • Radiation at 54Gy, chemotherapy (ACNU, vincristine) and gamma-knife surgery were performed, and two months later MR imaging showed that the tumor (including the ringed enhanced lesion) had shrunk markedly.
  • These cases suggest that radiation therapy is effective for gliomatosis cerebri.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16689395.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Vogelbaum MA, Peereboom D, Stevens G, Barnett G, Brewer C: Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results. J Clin Oncol; 2004 Jul 15;22(14_suppl):1558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results.
  • We have initiated the first phase II trial of erlotinib in single agent therapy of recurrent glioblastoma multiforme (GBM).
  • METHODS: Patients with documented recurrent or progressive GBM who have received previous radiation therapy and cytotoxic chemotherapy were eligible for enrollment.
  • Of these, 4 patients have shown partial responses, 1 showed a partial response of his original tumor but then developed a separate unresponsive focus and 4 have had disease stabilization for greater than 3 months.
  • Although a response has been seen in 50% of patients (4 PR + 4 SD), the responses have not been durable; the median time to progression of responders has been 145 days after the start of therapy.
  • The pattern of subsequent treatment failure in responders has suggested a diffuse spread of tumor (e.g. gliomatosis cerebri or leptomeningeal spread).
  • The apparent lack of durability of response and the pattern of post-response failure may be due, in part, to reduced drug penetration into the brain, an inadequate dose and/or tumor heterogeneity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015453.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH: Gliomatosis cerebri: improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys; 2003 Jul 15;56(4):1137-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomatosis cerebri: improved outcome with radiotherapy.
  • PURPOSE: Gliomatosis cerebri is a rare, diffuse involvement of the central nervous system by a malignant glioma that permeates the brain extensively without destroying the neural architecture and involves more than two lobes.
  • In this study, we sought to assess the role of radiotherapy (RT) and identify prognostic factors in gliomatosis cerebri.
  • METHODS AND MATERIALS: Thirty patients who received RT at a single institution and had radiographic follow-up were retrospectively reviewed with respect to outcome, radiation parameters, extent of surgery, and chemotherapy.
  • RESULTS: The median age at diagnosis was 38.6 years (range 16-68).
  • The mean radiation dose was 54.9 Gy, given in a mean of 28 fractions.
  • The median time to progression was 10 months, and it was significantly longer for patients <40 years old (p = 0.0007) and for patients having a tumor histologic subtype other than glioblastoma (p = 0.01).
  • Extensive surgery, administration of chemotherapy, or increased RT volume improved neither overall survival nor the time to disease progression.
  • CONCLUSION: RT is effective against gliomatosis cerebri.
  • In this analysis, no role for chemotherapy, extensive surgery, or whole-brain RT was found.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Neoplasms, Neuroepithelial / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12829152.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 77050-02
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


17. Fukushima Y, Nakagawa H, Tamura M: Combined surgery, radiation, and chemotherapy for oligodendroglial gliomatosis cerebri. Br J Neurosurg; 2004 Jun;18(3):306-10
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined surgery, radiation, and chemotherapy for oligodendroglial gliomatosis cerebri.
  • Gliomatosis cerebri (GC), which mainly consists of oligodendroglial tumour cells, is rare and six cases have been documented to date.
  • We present a new case of oligodendroglial gliomatosis cerebri with a favourable response to combination treatment using surgery, radiotherapy and chemotherapy.
  • [MeSH-major] Brain Neoplasms / surgery. Oligodendroglioma / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15327240.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 13
  •  go-up   go-down


18. Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB, Strik H, Wick W, Meyermann R, Dichgans J, Bamberg M, Reifenberger G, Weller M: Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol; 2002 Oct;52(4):390-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomatosis cerebri: molecular pathology and clinical course.
  • Gliomatosis cerebri is a rare, diffusely growing neuroepithelial tumor characterized by extensive brain infiltration involving more than two cerebral lobes.
  • Among 13 patients with gliomatosis cerebri (median age, 46 years), biopsies showed features of diffuse astrocytoma (n = 4), oligoastrocytoma (n = 1), anaplastic astrocytoma (n = 5), anaplastic oligoastrocytoma (n = 1), or glioblastoma (n = 2).
  • Four of six patients treated with procarbazine, carmustine, vincristine chemotherapy demonstrated partial remission (one patient), minor response (two patients), or stable disease (one patient).
  • Median survival time from diagnosis was 14 months (range, 4-91+ months).
  • We conclude that (1) the molecular genetic alterations in gliomatosis cerebri resemble those in diffuse astrocytomas;.
  • (2) the prognosis of gliomatosis cerebri is variable but for at least 50% of patients as poor as for glioblastoma; and (3) some patients respond to radiotherapy and/or procarbazine, carmustine, vincristine chemotherapy.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology. Nuclear Proteins
  • [MeSH-minor] Adult. Aged. Cause of Death. Combined Modality Therapy. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Female. Genetic Markers. Humans. Male. Middle Aged. PTEN Phosphohydrolase. Phosphoric Monoester Hydrolases / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-mdm2. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12325066.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Genetic Markers; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


19. Kumar V, Chakrabarti S, Modi M, Sahoo M: Late-onset obsessive compulsive disorder associated with possible gliomatosis cerebri. World J Biol Psychiatry; 2009;10(4 Pt 2):636-9
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-onset obsessive compulsive disorder associated with possible gliomatosis cerebri.
  • These include infections, degenerative disorders, brain injury and cerebrovascular lesions, principally involving the frontal lobes and basal ganglia.
  • The current patient had obsessive images, anxiety, auditory hallucinations and seizures following (possible) gliomatosis cerebri, with onset around 69 years of age.
  • However, late-onset OCD has not been commonly reported with diffuse lesions, and the association with gliomatosis cerebri is not known.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis. Obsessive-Compulsive Disorder / diagnosis
  • [MeSH-minor] Aged. Anticonvulsants / therapeutic use. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Choline / metabolism. Corpus Callosum / pathology. Dominance, Cerebral / physiology. Drug Therapy, Combination. Epilepsy, Tonic-Clonic / diagnosis. Epilepsy, Tonic-Clonic / drug therapy. Epilepsy, Tonic-Clonic / psychology. Hippocampus / pathology. Humans. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Male. Parietal Lobe / pathology. Temporal Lobe / pathology


20. Kaloshi G, Guillevin R, Martin-Duverneuil N, Laigle-Donadey F, Psimaras D, Marie Y, Mokhtari K, Hoang-Xuan K, Delattre JY, Sanson M: Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebri. Neurology; 2009 Aug 11;73(6):445-9
Genetic Alliance. consumer health - Gliomatosis Cerebri.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebri.
  • BACKGROUND: In gliomatosis cerebri (GC), defined as a diffuse neoplastic glial cell infiltration of the brain, upfront chemotherapy is often proposed as an alternative to radiotherapy.
  • METHODS: The GMI was estimated in 71 patients with GC (42 men and 29 women; median age, 47 years) treated with upfront chemotherapy (7 PCV, 64 temozolomide).
  • Compared to the 33 patients with GMI >30% (group B), the 38 patients from group A (defined as GMI <or=30%) had better performance status (p = 0.03), higher response rate to chemotherapy (30/38 vs only 5/33; p < 0.0001), longer progression-free survival (21.2 vs 11.7 months, p = 0.005), and longer overall survival (56.1 vs 26.4 months; p = 0.003).
  • CONCLUSION: These data suggest that gray matter index is a prognostic and predictive marker in gliomatosis cerebri that may in part depend on the 1p/19q status.
  • [MeSH-major] Cerebral Cortex / pathology. Neoplasms, Neuroepithelial / diagnosis. Neoplasms, Neuroepithelial / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Movement / physiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neuroglia / pathology. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667319.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Vates GE, Chang S, Lamborn KR, Prados M, Berger MS: Gliomatosis cerebri: a review of 22 cases. Neurosurgery; 2003 Aug;53(2):261-71; discussion 271
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomatosis cerebri: a review of 22 cases.
  • OBJECTIVE: Gliomatosis cerebri is an enigmatic diffuse brain neoplasm whose prognosis is grim.
  • We reviewed data for patients with gliomatosis who were treated at the University of California, San Francisco, during a 10-year period.
  • METHODS: We reviewed hospital and clinic records and magnetic resonance imaging scans for 22 patients with gliomatosis.
  • The diagnosis was based on magnetic resonance imaging findings and tissue confirmation for all patients.
  • RESULTS: Kaplan-Meier analysis demonstrated median lengths of survival as follows: no treatment, 1 month (n = 4); radiotherapy alone, 28 months (95% confidence interval, 5-51 mo; n = 13); radiotherapy followed by chemotherapy, two patients, alive at 28 and 104 months; radiotherapy and chemotherapy simultaneously, three patients, one alive at 18 months and the others dead at 7 and 9 months.
  • There was no significant difference between radiotherapy alone and radiotherapy combined with chemotherapy (P = 0.69).
  • CONCLUSION: Although the small number of patients in our study and its retrospective nature preclude definitive conclusions regarding the utility of treatment, our findings suggest that biopsies are useful not only for diagnosis but also for prediction of the length of survival.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Neoplasms, Neuroepithelial / diagnosis. Neoplasms, Neuroepithelial / therapy


22. Glas M, Rasch K, Wiewrodt D, Weller M, Herrlinger U: Procarbazine and CCNU as initial treatment in gliomatosis cerebri. Oncology; 2008;75(3-4):182-5
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Procarbazine and CCNU as initial treatment in gliomatosis cerebri.
  • BACKGROUND: Gliomatosis cerebri (GC) is a diffuse infiltrating glial tumor with involvement of at least 3 cerebral lobes.
  • There are only few data on the efficacy of initial chemotherapy in patients with GC.
  • PATIENTS AND METHODS: In 3 neurooncological centers, patients with newly diagnosed GC who had received procarbazine (60 mg/m(2), days 8-21/56) and CCNU (110 mg/m(2), day 1/56) chemotherapy (PC) as initial treatment were analyzed for progression-free survival, overall survival and toxicity.
  • CONCLUSIONS: These data support the efficacy of PC chemotherapy in newly diagnosed GC.
  • Initial PC chemotherapy should be considered as a treatment option and evaluated in larger clinical trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Neuroepithelial / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Disease-Free Survival. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Pilot Projects. Procarbazine / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18841032.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


23. Romeike B, Mawrin C: Gliomatosis cerebri: growing evidence for diffuse gliomas with wide invasion. Expert Rev Neurother; 2008 Apr;8(4):587-97
MedlinePlus Health Information. consumer health - Clinical Trials.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomatosis cerebri: growing evidence for diffuse gliomas with wide invasion.
  • Recent evidence suggests that there are no features that sufficiently distinguish gliomatosis cerebri (GC) from diffuse gliomas.
  • These data implicate that treatment guidelines might follow those for diffuse gliomas in general.
  • The role of whole brain radiotherapy is unclear because no impact on survival could be demonstrated.
  • At least some patients might benefit from chemotherapy (temozolomide).
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Clinical Trials as Topic / trends. Evidence-Based Medicine / trends. Neoplasms, Neuroepithelial / diagnosis. Neoplasms, Neuroepithelial / therapy. Practice Patterns, Physicians' / trends
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416661.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 94
  •  go-up   go-down


24. Yamada SM, Hayashi Y, Takahashi H, Teramoto A, Matsumoto K, Yamada S: Histological and genetic diagnosis of gliomatosis cerebri: case report. J Neurooncol; 2001 May;52(3):237-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and genetic diagnosis of gliomatosis cerebri: case report.
  • Gliomatosis cerebri is considered grade III astrocytoma because of the short survival period of patients with this tumor, while the tumor histologically consists of widespread low grade astrocytoma cells.
  • Histological diagnosis was gliomatosis cerebri with diffuse grade II astrocytoma.
  • Seven months after temporary improvement following irradiation and chemotherapy, he developed progressive mental deterioration, and died in one year after the surgery.
  • At this time T1-weighted imaging showed Gd-enhanced lesions with enlargement only of the cerebellar tumor.
  • Genetic analysis demonstrated positive FGFR 1 and less FGFR 2 mRNA in the tumor tissue, and FGFR 1 mRNA was beta type dominant.
  • The authors conclude that genetic investigation of the tumor tissue is required to predict the prognosis of gliomatosis cerebri patients, in addition to imaging and histological examinations.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis
  • [MeSH-minor] Adult. Antigens, Nuclear. Biomarkers, Tumor / genetics. Cerebellar Neoplasms / chemistry. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / genetics. Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Combined Modality Therapy. Contrast Media. Fatal Outcome. Gadolinium DTPA. Humans. Magnetic Resonance Imaging. Male. Neoplasm Proteins / genetics. Nuclear Proteins / analysis. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Receptor Protein-Tyrosine Kinases / genetics. Receptor, Fibroblast Growth Factor, Type 1. Receptor, Fibroblast Growth Factor, Type 2. Receptors, Fibroblast Growth Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroradiology. 1999 Sep;41(9):650-3 [10525765.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):755-62 [9810441.001]
  • [Cites] Scott Med J. 1998 Jun;43(3):84-6 [9682295.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1789-93 [8859193.001]
  • [Cites] AJR Am J Roentgenol. 1993 Oct;161(4):859-62 [8372774.001]
  • [Cites] Clin Neuropathol. 1985 Jul-Aug;4(4):135-48 [4053456.001]
  • [Cites] Neuroradiology. 1996 Jul;38(5):444-8 [8837088.001]
  • [Cites] Radiology. 1996 Mar;198(3):831-5 [8628879.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):484-8 [8290551.001]
  • [Cites] Pediatr Neurol. 1999 Feb;20(2):148-51 [10082346.001]
  • [Cites] Acta Radiol. 1997 May;38(3):381-90 [9191428.001]
  • [Cites] Surg Neurol. 1991 Dec;36(6):431-40 [1759182.001]
  • [Cites] Brain Tumor Pathol. 1998;15(2):111-6 [10328549.001]
  • [Cites] Eur J Radiol. 1998 Oct;28(3):226-9 [9881257.001]
  • [Cites] Glia. 1999 Oct;28(1):66-76 [10498824.001]
  • [Cites] No To Shinkei. 1996 Apr;48(4):363-70 [8679334.001]
  • (PMID = 11519853.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Fibroblast Growth Factor; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / FGFR2 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


25. Arai M, Kashihara K, Kaizaki Y, Taguchi M, Kitamura Y: [Gliomatosis cerebri: report of 3 cases and review of recent literatures]. No To Shinkei; 2003 Oct;55(10):890-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gliomatosis cerebri: report of 3 cases and review of recent literatures].
  • Gliomatosis cerebri is a rare tumor of the central nervous system characterized by widespread diffuse infiltration of the brain and spinal cord by neoplastic glial cells.
  • The diagnosis of gliomatosis cerebri with MR imaging remains difficult.
  • We presented three interesting cases of gliomatosis cerebri.
  • Case 1 showed transformation from type 1 gliomatosis cerebri to type 2.
  • Case 2 showed that the initial thalamic lesion extended into brain stem, cerebellar hemisphere and right cerebral hemisphere.
  • After radiation therapy, the right cerebral cortex demonstrated hyperintensity on T1- and hypointensity on T2-weighted image.
  • These two cases did not demonstrate diffuse brain swelling or indistinctness of gray/white matter border on the first MR imaging.
  • Case 3 improved in response to radiotherapy and chemotherapy using procarbazine/MCNU/vincristine (MVP).
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / pathology. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14635518.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine
  • [Number-of-references] 11
  •  go-up   go-down


26. Val Filho JA, Avelar LG: Gliomatosis cerebri with favorable outcome in a child: a case report. J Pediatr (Rio J); 2008 Sep-Oct;84(5):463-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomatosis cerebri with favorable outcome in a child: a case report.
  • OBJECTIVE: To report a rare clinical case of gliomatosis cerebri with favorable outcome in a 3-year old child.
  • DESCRIPTION: A 3-year old child developed severe and progressive symptoms of gliomatosis cerebri.
  • She also received chemotherapy and radiotherapy.
  • Currently, 6 years later, spinal canal and brain injuries remain unaltered, with marked syringomyelia.
  • However, the child is clinically stable, with adequate development for her age, indicating a satisfactory response to treatment.
  • COMMENTS: The child's clinical presentation and the combination of symptoms led to the diagnosis of gliomatosis cerebri.
  • [MeSH-major] Brain Neoplasms / therapy. Neoplasms, Neuroepithelial / therapy
  • [MeSH-minor] Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Treatment Outcome

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr (Rio J). 2009 May-Jun;85(3):277-9; author reply 279-80 [19492175.001]
  • (PMID = 18833342.001).
  • [ISSN] 1678-4782
  • [Journal-full-title] Jornal de pediatria
  • [ISO-abbreviation] J Pediatr (Rio J)
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


27. Taillibert S, Chodkiewicz C, Laigle-Donadey F, Napolitano M, Cartalat-Carel S, Sanson M: Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol; 2006 Jan;76(2):201-5
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature.
  • Gliomatosis cerebri (GC) is a rare disease, defined as a diffuse neoplastic glial cell infiltration of the brain.
  • Diagnosis and management of GC are difficult.
  • It was higher for patients younger than 42 years (17 months vs. 13 months), with performance status>or=80 (27 months vs. 9 months), low grade gliomatosis (grade 2=20 months, grade 3=11.5 months, grade 4=8.5 months), oligodendroglial subtype (36 months compared to 14 months for mixed GC and 11 months for astrocytic GC).
  • Despite a high rate of stabilization, the impact on survival of whole brain radiotherapy, which carries the risk of severe toxicity, is still unclear.
  • Up-front chemotherapy benefit to some patients and may be preferred to whole brain radiotherapy.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Databases, Factual. Female. France / epidemiology. Humans. Infant. Karnofsky Performance Status. Male. Middle Aged. Prognosis. Registries. Sex Factors. Survival Analysis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1952 Jul;9(4):409-17 [14946583.001]
  • [Cites] Clin Neuropathol. 1991 Nov-Dec;10 (6):303-5 [1764854.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Sep;61(9):806-14 [12230327.001]
  • [Cites] J Neurosurg. 1993 Jan;78(1):158-9 [8416236.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):275-8 [2703845.001]
  • [Cites] Brain Tumor Pathol. 1997;14(1):53-7 [9384803.001]
  • [Cites] Neuroradiology. 1996 Nov;38(8):774-7 [8957803.001]
  • [Cites] Acta Neurol Belg. 1996 Dec;96(4):294-300 [9008778.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):755-62 [9810441.001]
  • [Cites] Neurology. 2001 Oct 9;57(7):1278-81 [11591848.001]
  • [Cites] Magn Reson Imaging. 2003 Nov;21(9):1003-7 [14684203.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):726-8 [2013813.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1789-93 [8859193.001]
  • [Cites] Surg Neurol. 2002 Jun;57(6):399-404; discussion 404 [12176200.001]
  • [Cites] Acta Neuropathol Suppl. 1981;7:101-4 [7013410.001]
  • [Cites] Br J Neurosurg. 1991;5(2):187-93 [1650563.001]
  • [Cites] Neurology. 2001 Nov 27;57(10 ):1932-3 [11723300.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Jan-Feb;13(1):349-51 [1595474.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Child Neurol. 1995 Jan;10(1):37-45 [7539465.001]
  • [Cites] Acta Neurochir (Wien). 1991;113(3-4):131-7 [1799156.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Oct;14(2):149-53 [8527397.001]
  • [Cites] Postgrad Med J. 1995 Aug;71(838):483-4 [7567756.001]
  • [Cites] Neurology. 1974 Jun;24(6):504-11 [4499966.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):270-5 [15277619.001]
  • [Cites] Acta Oncol. 2000;39(6):747-51 [11130015.001]
  • [Cites] Neuroradiology. 1992;34(4):331-3 [1528447.001]
  • [Cites] J Neurosurg. 1978 Aug;49(2):303-7 [671086.001]
  • [Cites] J Neurol. 1991 Apr;238(2):80-2 [1856741.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):354-6 [15277636.001]
  • [Cites] Ann Neurol. 2002 Oct;52(4):390-9 [12325066.001]
  • [Cites] Clin Neuropathol. 1995 Jan-Feb;14 (1):13-8 [7729074.001]
  • [Cites] Clin Neuropathol. 1985 Jul-Aug;4(4):135-48 [4053456.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;411(1):93-8 [3107212.001]
  • [Cites] J Clin Neurosci. 2001 Jul;8(4):361-3 [11437581.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):706-7 [1592395.001]
  • [Cites] Neuroradiology. 1996 Jul;38(5):444-8 [8837088.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):175-8 [9120548.001]
  • [Cites] Br J Neurosurg. 1996 Feb;10 (1):103-7 [8672252.001]
  • [Cites] Radiology. 1996 Mar;198(3):831-5 [8628879.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1137-46 [12829152.001]
  • [Cites] Folia Neuropathol. 1994;32(4):245-9 [7889339.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):249-59 [12241123.001]
  • [Cites] Acta Radiol. 1997 May;38(3):381-90 [9191428.001]
  • [Cites] Acta Cytol. 1981 Jan-Feb;25(1):37-9 [6937066.001]
  • [Cites] Surg Neurol. 1991 Dec;36(6):431-40 [1759182.001]
  • [Cites] Mov Disord. 2004 Mar;19(3):341-4 [15022192.001]
  • [Cites] Ital J Neurol Sci. 1992 Sep;13(6):503-6 [1428787.001]
  • [Cites] Intern Med. 2003 Jul;42(7):615-8 [12879957.001]
  • [Cites] J Neurooncol. 2003 Jan;61(1):1-5 [12587789.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):2027-31 [12404298.001]
  • [Cites] Neuroradiology. 1987;29(1):15-8 [3822096.001]
  • [Cites] Postgrad Med J. 1995 Jun;71(836):380-1 [7644408.001]
  • [Cites] Arq Neuropsiquiatr. 1997 Sep;55(3A):488-95 [9629370.001]
  • [Cites] Cogn Behav Neurol. 2003 Sep;16(3):149-59 [14501536.001]
  • (PMID = 16200347.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Inoue T, Kanamori M, Sonoda Y, Watanabe M, Sasajima T, Kamisato N, Kumabe T, Tominaga T: [Glioblastoma multiforme developing separately from the initial lesion 9 years after successful treatment for gliomatosis cerebri: a case report]. No Shinkei Geka; 2008 Aug;36(8):709-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glioblastoma multiforme developing separately from the initial lesion 9 years after successful treatment for gliomatosis cerebri: a case report].
  • Gliomatosis cerebri is a diffuse growth pattern of glioma consisting of exceptionally extensive infiltration of at least three cerebral lobes.
  • We report a case of histologically confirmed glioblastoma multiforme in the cerebellar vermis which occurred 9 years after treatment for gliomatosis cerebri.
  • Histological examination of biopsy specimens from the left frontal lobe lesion demonstrated diffuse infiltration of glial neoplastic cells with preservation of the underlying cytoarchitecture, leading to the diagnosis of gliomatosis cerebri.
  • She received 60 Gy hyperfractionated irradiation to the whole brain, and the lesion responded partially.
  • The patient remained stable for 4 years, but T2-weighted MR imaging 5 years after the initial treatment showed enlargement of the hyperintense area.
  • She received nimustine hydrochloride chemotherapy, and again partial response was observed. However.
  • T1-weighted MR imaging after administration of gadolinium-diethylenetriaminepenta-acetic acid detected enhanced lesions in the cerebellar vermis, cerebellar hemisphere, and left posterior limb of the internal capsule 9 years after the initial treatment, although no abnormal findings were observed on initial and follow-up MR imaging.
  • The histological diagnosis was glioblastoma multiforme.
  • The patient received gamma knife irradiation for the remnant lesion in the cerebellar vermis, and the lesions in the cerebellar hemisphere and left posterior limb of the internal capsule, and chemotherapy with temozolomide.
  • However, multiple enhanced lesions were detected in the cerebellar vermis 2 months after the start of the temozolomide chemotherapy, and she died 8 months later.
  • This case suggests that glioblastoma multiforme could develop in the long term after initial treatment for gliomatosis cerebri, and in a location separate from the initial lesion.
  • [MeSH-major] Brain Neoplasms / therapy. Cerebellum. Glioblastoma / therapy. Neoplasms, Neuroepithelial / therapy. Neoplasms, Second Primary
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Dose Fractionation. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Radiosurgery. Time Factors

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18700534.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 12
  •  go-up   go-down


29. Akai H, Mori H, Aoki S, Masutani Y, Kawahara N, Shibahara J, Ohtomo K: Diffusion tensor tractography of gliomatosis cerebri: fiber tracking through the tumor. J Comput Assist Tomogr; 2005 Jan-Feb;29(1):127-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion tensor tractography of gliomatosis cerebri: fiber tracking through the tumor.
  • In previous reports, tracts obtained by diffusion tensor (DT) fiber tracking were terminated or deviated by the brain tumors or surrounding edema.
  • A case of glioma is reported, whose DT fiber tract passing through the tumor was observed by changing the threshold of fractional anisotropy.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Neoplasms, Neuroepithelial / pathology. Pyramidal Tracts / pathology

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665698.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Piccirilli M, Landi A, Salvati M: Gliomatosis cerebri treatment in 11 elderly patients. J Exp Clin Cancer Res; 2006 Jun;25(2):183-7
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomatosis cerebri treatment in 11 elderly patients.
  • The Authors report their experience in the treatment of eleven patients over 70 years old (range from 70 to 83, average age 74.8, 7 males and 4 females), with histologically proven diagnosis of glioblastoma multiforme.
  • The GC golden standard treatment is still debated, particularly in elderly patients.
  • All the patients underwent a first line treament with chemotherapy (Temozolomide), followed by Whole Brain Radiotherapy (WBRT) and PCV schedule without Vincristine in case of progression of the disease.
  • According to our experience, elderly patients should undergo the same treatment of younger patients, provided they are in good health conditions.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Neoplasms, Neuroepithelial / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Disease Progression. Female. Humans. Lomustine / administration & dosage. Magnetic Resonance Imaging. Male. Procarbazine / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918128.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


31. Gilmer-Hill HS, Ellis WG, Imbesi SG, Boggan JE: Spinal oligodendroglioma with gliomatosis in a child. Case report. J Neurosurg; 2000 Jan;92(1 Suppl):109-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal oligodendroglioma with gliomatosis in a child. Case report.
  • At 2.5 years of age this boy developed poor balance, neck stiffness, and a regression in developmental milestones.
  • A computerized tomography (CT) scan of the head initially revealed ventriculomegaly and multiple cystic cerebellar lesions.
  • These findings were compatible with a diagnosis of oligodendrogliomatosis cerebri.
  • Despite having a complicated course, chemotherapy with carboplatin has provided the patient with long-term palliation and a high quality of life.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Neoplasms, Multiple Primary / pathology. Oligodendroglioma / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Palliative Care. Photomicrography. Tomography, X-Ray Computed


32. Liu L, Vapiwala N, Munoz LK, Winick NJ, Weitman S, Strauss LC, Frankel LS, Rosenthal DI: A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors. Med Pediatr Oncol; 2001 Oct;37(4):390-2
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors.
  • We performed a multi-institutional phase I study to determine the toxicities and tolerance of concurrent external beam radiation of the brain and a unique dose-schedule of paclitaxel as a radiation sensitizer.
  • PROCEDURE: Paclitaxel was delivered intravenously as a continuous 24 h/day, 7 days/week infusion during the entire 6-week course of fixed schedule standard radiation therapy.
  • RESULTS: Eleven patients (eight brain stem gliomas, one glioblastoma multiforme, and two gliomatosis cerebri) were treated.
  • Dose-limiting toxicity was encountered in the two patients treated at 6 mg/(m(2)/24 h), both of whom developed severe obstipation requiring prolonged hospitalization.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Paclitaxel / administration & dosage. Radiation-Sensitizing Agents / administration & dosage. Radiotherapy, High-Energy / methods
  • [MeSH-minor] Adolescent. Brain / radiation effects. Child. Child, Preschool. Combined Modality Therapy. Drug Administration Schedule. Female. Follow-Up Studies. Glioblastoma / drug therapy. Glioblastoma / mortality. Glioblastoma / pathology. Glioblastoma / radiotherapy. Glioma / drug therapy. Glioma / mortality. Glioma / pathology. Glioma / radiotherapy. Humans. Infusions, Intravenous. Male. Radiation Injuries / prevention & control. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11568904.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


33. Heimberger AB, Suki D, Yang D, Shi W, Aldape K: The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med; 2005 Oct 19;3:38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Biopsed or partially/subtotally resected GBM patients (N = 54) underwent adjuvant conformal radiation and chemotherapy.
  • RESULTS: In our study of GBM patients with less than GTR, 42.6% (n = 23) failed to express EGFR, 25.9% (n = 14) had over expression of the wild-type EGFR only and 31.5 % (n = 17) expressed the EGFRvIII.
  • They all had received postoperative radiation and chemotherapy.
  • The median overall survival times for patients with tumors having no EGFR expression, over expressed EGFR only, or EGFRvIII were 12.3 (95% CI, 8.04-16.56), 11.03 (95% CI, 10.18-11.89) and 14.07 (95% CI, 7.39-20.74) months, respectively, log rank test p > 0.05).
  • There was no significant difference in multifocal disease or gliomatosis cerebri among EGFR expression groups.
  • CONCLUSION: The over expressed wild-type EGFR and EGFRvIII are not independent predictors of median overall survival in the cohort of patients who did not undergo extensive tumor resection.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Invasion Metastasis. 1997;17(5):270-80 [9876221.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7 [15290895.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1462-6 [15746047.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1394-400 [1873791.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2164-72 [2009534.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6039-44 [2393868.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):487-93 [2552044.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4375-82 [7671250.001]
  • [Cites] Oncogene. 1994 Aug;9(8):2313-20 [8036013.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):809-15 [8598357.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):634-41 [8814167.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4130-40 [9307304.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Int J Oncol. 1998 Oct;13(4):717-24 [9735401.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2383-90 [9796969.001]
  • [Cites] Brain Pathol. 1998 Oct;8(4):655-67 [9804374.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Oct;24(5):381-8 [9821169.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • (PMID = 16236164.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1298339
  •  go-up   go-down


34. Soffietti R, Leoncini B, Rudà R: New developments in the treatment of malignant gliomas. Expert Rev Neurother; 2007 Oct;7(10):1313-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New developments in the treatment of malignant gliomas.
  • Malignant gliomas represent an heterogeneous group of brain tumors both in terms of natural history and response to treatment.
  • The standard therapeutic approach for treating glioblastomas is a combination of radiotherapy and concomitant/adjuvant temozolomide, and methylguanine-DNA methyltransferase promoter methylation is now recognized as an important factor for predicting both prognosis and response to alkylating agents.
  • In the future, the discovery of targeted therapies will increasingly allow personalized medical treatments.
  • Anaplastic oligodendroglial tumors display a better prognosis and are more chemosensitive than glioblastomas; the discovery of molecular factors of prognostic significance, such as 1p/19q codeletion, will lead to different treatment strategies for different subgroups of patients.
  • Gliomatosis cerebri is a rare diffuse glioma, and upfront chemotherapy is increasingly being employed instead of whole-brain radiotherapy to avoid/delay cognitive defects in long surviving patients, despite the lack of data to support this.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioma / drug therapy. Glioma / radiotherapy
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Drugs, Investigational / therapeutic use. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939769.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational
  • [Number-of-references] 144
  •  go-up   go-down


35. Jeannin S, Lebrun C, Van Den Bos F, Olschwang S, Bourg V, Frenay M: [Turcot's syndrome confirmed by molecular biological tests]. Rev Neurol (Paris); 2006 Jun;162(6-7):741-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Syndrome de Turcot confirmé par biologie moléculaire.
  • INTRODUCTION: Turcot's syndrome is characterized clinically by the concurrence of a primary brain tumor and a familial adenomatous polyposis or a hereditary nonpolyposis colorectal cancer.
  • OBSERVATION: We report a case of a 45-year-old woman who underwent in 1995 neuro-oncological treatment for an anaplastic astrocytoma (grade III according to the World Health Organization classification).
  • Treatment included complete surgery, radiotherapy, a first-line nitrosourea-based chemotherapy regimen and a second-line platinium salt-based regimen.
  • Eight years after the diagnosis, the patient developed a gliomatosis cerebri and died.
  • CONCLUSION: Relevant personal and familial history can provide the clue to the diagnosis of Turcot's syndrome.
  • Molecular diagnosis may contribute to appropriate care of affected patients.
  • [MeSH-major] Adenomatous Polyps / complications. Adenomatous Polyps / genetics. Brain Neoplasms / complications. Carrier Proteins / genetics. Colorectal Neoplasms / complications. Colorectal Neoplasms / genetics. DNA Mutational Analysis / methods. Glioma / complications. MutS Homolog 2 Protein / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Colonoscopy / methods. Combined Modality Therapy. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Pedigree. Point Mutation / genetics. Syndrome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840983.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


36. Riel-Romero RM, Baumann RJ, Smith CD: An unusual complication of cancer treatment for acute lymphoblastic leukemia. J Neurooncol; 2005 Jul;73(3):269-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual complication of cancer treatment for acute lymphoblastic leukemia.
  • As more aggressive therapeutic regimens have been adopted and ostensibly cured patients are being followed for longer periods of time, it has become increasingly clear that the treatment of cancer can have significant late effects on the growing child, one of the more troublesome of which is the induction of secondary malignancy.
  • We report an 11-year-old child who, as supported by both clinical course and neuroimaging studies, developed an unusual complication eight years after completing therapy for acute lymphoblastic leukemia, gliomatosis cerebri.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology. Neoplasms, Second Primary / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Feb;21(2):375-80 [10696026.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Clin Neuropathol. 1991 Nov-Dec;10 (6):303-5 [1764854.001]
  • [Cites] J Neurosurg. 1993 Jan;78(1):158-9 [8416236.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):726-8 [2013813.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Oct;15(9):1745-53 [7847223.001]
  • [Cites] Neurosurgery. 2003 Aug;53(2):261-71; discussion 271 [12925240.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2186-95 [7697611.001]
  • [Cites] Eur Radiol. 2001;11(2):309-16 [11218033.001]
  • [Cites] J Child Neurol. 1995 Jan;10(1):37-45 [7539465.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Oct;14(2):149-53 [8527397.001]
  • [Cites] Neurology. 1974 Jun;24(6):504-11 [4499966.001]
  • [Cites] AJNR Am J Neuroradiol. 1988 Jan-Feb;9(1):200-2 [3124573.001]
  • [Cites] Neurology. 1956 Apr;6(4):269-74 [13309606.001]
  • [Cites] J Comput Assist Tomogr. 1988 Jul-Aug;12 (4):698-701 [3392285.001]
  • [Cites] Clin Neuropathol. 1985 Jul-Aug;4(4):135-48 [4053456.001]
  • [Cites] Med Pediatr Oncol. 2003 Dec;41(6):562-4 [14595716.001]
  • [Cites] Leuk Lymphoma. 1994 Mar;13(1-2):183-6 [8025519.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):83-7 [15068830.001]
  • [Cites] Pediatr Neurol. 1999 Feb;20(2):148-51 [10082346.001]
  • [Cites] Surg Neurol. 1991 Dec;36(6):431-40 [1759182.001]
  • [Cites] J Neurol. 1987 Aug;234(6):445-7 [3655852.001]
  • [Cites] Neuroradiology. 1987;29(1):15-8 [3822096.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • (PMID = 15980979.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC, Iacono LC, Merchant TE, Stewart CF, Houghton PJ, Kun LE, Ledet D, Gajjar A: Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol; 2006 Feb;76(3):313-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapy is commonly used in the treatment of children with high-grade glioma, although its usefulness is uncertain.
  • We conducted a multi-institutional study to evaluate the efficacy of temozolomide given after radiotherapy in children with newly diagnosed high-grade glioma and unfavorable low-grade glioma (gliomatosis cerebri or bithalamic involvement).
  • Optional window therapy of intravenous irinotecan (10 doses of 20 mg/m2 per cycle x 2) was given over 6 weeks.
  • Twenty-seven patients received radiotherapy (median dose: 59.4 Gy), including craniospinal irradiation in 3 because of leptomeningeal spread.
  • Four patients did not receive radiotherapy in this study because of consent withdrawn (n = 2), toxicity during window therapy (n = 1), or at the physician's discretion (n = 1).
  • Twenty-three patients received 112 cycles of temozolomide therapy.
  • Although the heterogeneity of prognostic factors in our patients made assessment of treatment outcome more difficult, the addition of 6 cycles of temozolomide after radiotherapy did not seem to alter the poor outcome of these patients.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1976 Dec;34(6):585-612 [795448.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12 ):3851-7 [9850030.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):261-7 [12356356.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):425-9 [15266331.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] Br J Cancer. 1998 Sep;78(5):652-61 [9744506.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Dec;52(6):435-41 [13680158.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3037-43 [9738573.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):197-207 [12816726.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):817-24 [15305415.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):133-9 [15565574.001]
  • [Cites] Clin Neuropathol. 2001 Nov-Dec;20(6):248-55 [11758780.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):258-64 [8869052.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2131-7 [11066055.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):41-8 [15701281.001]
  • (PMID = 16200343.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA21765
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; 7GR28W0FJI / Dacarbazine; XT3Z54Z28A / Camptothecin; YF1K15M17Y / temozolomide
  •  go-up   go-down


38. Benjelloun A, Delavelle J, Lazeyras F, Dietrich PY: Possible efficacy of temozolomide in a patient with gliomatosis cerebri. Neurology; 2001 Nov 27;57(10):1932-3
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible efficacy of temozolomide in a patient with gliomatosis cerebri.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Neoplasms, Neuroepithelial / drug therapy
  • [MeSH-minor] Adult. Brain / pathology. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11723300.001).
  • [ISSN] 0028-3878
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down






Advertisement